

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-427US1	Application No. 10/520,699
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Hossain et al.	
		Filing Date January 7, 2005	Group Art Unit 1625

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	AA	Brown et al., "Novel CCR1 antagonists with improved metabolic stability", <i>Bioorg. Med. Chem. Lett.</i> 14:2175-2179 (2004)
	AB	Martin et al., "Do Structurally Similar Molecules Have Similar Biological Activity?", <i>J. Med. Chem.</i> 45:4350-4358 (2002)
	AC	Pozharskii et al., <i>Heterocycles in Life and Society</i> . Wiley, 1997, pp. 1-6
	AD	Thoma et al., "Orally Bioavailable Competitive CCR5 Antagonists", <i>J. Med. Chem.</i> 47:1939-1955 (2004)
	AE	Thomson et al., <i>The Cytokine Handbook</i> , 4 th ed. New York, Academic Press, 2003, pp. 1084-1087
	AF	Ting et al., "The synthesis of substituted biperidine amide compounds as CCR3 ligands: Antagonists versus agonists", <i>Bioorg. Med. Chem. Lett.</i> 15:3020-3023 (2005)
	AG	Xie et al., "Identification of novel series of human CCR1 antagonists", <i>Bioorg. Med. Chem. Lett.</i> 18:2215-2221 (2008)
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	
	AO	
	AP	
	AQ	
	AR	
	AS	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /CA/

Examiner Signature /Charanjit Aulakh/	Date Considered 07/17/2008
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	